Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study

ConclusionsIn this large-scale Italian observational multi-database study, switching versus non-switching as well as switching from biosimilar/originator ESA  α to any other epoetin in CKD patients is not associated with any effectiveness and safety outcomes.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research

Related Links:

Abstract Recombinant human erythropoietin (rhEPO) is a glycoprotein that acts as the main hormone involved in regulating red blood cell production to treat anemia caused by chronic kidney disease or chemotherapy. Since the expiration of the patent of the innovator epoetin alfa, numerous rhEPO products have emerged in global markets. As described here, multiple complementary analytical approaches are utilized for the extensive characterization of rhEPO molecules, and more importantly for the structural comparison of the rhEPO analogues on the Chinese market. The focus of this study is placed on the overall glycosyl...
Source: Talanta - Category: Chemistry Authors: Tags: Talanta Source Type: research
ObjectivesTo evaluate the efficacy of Traditional Chinese Medicine, specifically Jianpi Bushen (JPBS) therapy, for treatment of patients with chronic kidney disease (CKD) anemia.MethodsRandomized controlled trials of JPBS therapy for CKD anemia were searched and selected from seven electronic databases. The Cochrane collaboration tool was used to conduct methodological quality assessment. RevMan v5.3 software was utilized to perform data analysis.ResultsIn total, 12 randomized controlled trials with 799 patients met the meta-analysis criteria. The aggregated results indicated that JPBS therapy is beneficial for CKD anemia ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Source: Clinical Epidemiology - Category: Epidemiology Tags: Clinical Epidemiology Source Type: research
This article summarizes the milestones in the development of daprodustat leading to this first approval for the treatment of renal anaemia.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Authors: Wang B, Yin Q, Han YC, Wu M, Li ZL, Tu Y, Zhou LT, Wei Q, Liu H, Tang RN, Cao JY, Lv LL, Liu BC Abstract Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are orally active first-in-class new generation drugs for renal anemia. This extensive meta-analysis of randomized controlled trials (RCTs) was designed to provide clear information on the efficacy and safety of HIF-PHIs on anemia in chronic kidney disease (CKD) patients. Searches included PubMed, Web of Science, Ovid MEDLINE, and Cochrane Library database up to October 2019. RCTs of patients with CKD comparing HIF-PHIs with erythropoiesi...
Source: Renal Failure - Category: Urology & Nephrology Tags: Ren Fail Source Type: research
Conclusions Routine preoperative laboratory testing does not identify clinically meaningful abnormalities or alter surgical management in women undergoing urogynecologic surgery.
Source: Journal of Pelvic Medicine and Surgery - Category: Surgery Tags: Original Articles Source Type: research
Conclusion: HIF-PHIs ameliorate renal anemia and rectify iron metabolism in the short term without increasing the incidence of AEs and SAEs.Nephron
Source: Nephron - Category: Urology & Nephrology Source Type: research
This study aimed to investigate the risk factors for ABT and 1-year mortality in elderly patients undergoing surgery for femoral neck fracture. A total of 225 elderly patients who underwent femoral neck fracture surgery between May 2013 and November 2015 at a tertiary medical center were retrospectively recruited. Medical records were analyzed. The median patient age was 80 years and 28.4% were men. A total of 113 patients received ABT (50.2%). Multivariate logistic regression analysis showed that female sex (odds ratio [OR] 2.606, 95% confidence interval [CI] 1.283–5.295, Pā€Š=ā€Š.008), malignancy (OR 5.098, 95% C...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
This article summarizes the milestones in the development of vadadustat leading to this first approval.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
VAFSEO Launch Marks Availability of Convenient Once-Daily Oral Treatment for Adult Patients on Dialysis and Not on Dialysis in Japan CAMBRIDGE, Mass., Aug. 26, 2020 -- (Healthcare Sales &Marketing Network) -- Akebia Therapeutics®, Inc. (Nasdaq: AK... Biopharmaceuticals, Product Launch Akebia Therapeutics, vadadustat, VAFSEO , chronic kidney disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Anemia | Chronic Kidney Disease | Databases & Libraries | Drugs & Pharmacology | Italy Health | Marketing | Study | Urology & Nephrology